文献速递肿瘤 PET/CT神经核医学

[18F]FDG PET-MRI 为老年原发性中枢神经系统淋巴瘤提供生存生物标志物:LOC 网络 BLOCAGE 试验的辅助研究

[18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-07-18

研究前瞻性纳入 60 岁以上免疫功能正常的初诊原发性中枢神经系统淋巴瘤(PCNSL)患者,于大剂量甲氨蝶呤化疗前行脑 [18F]FDG PET-MRI。基线小脑代谢和 sumMTV 可能预测化疗结束时的缓解,肿瘤体积和 MILAS 是强预后因素。

要点

  • 基线小脑 SUVmean 较高和 sumMTV 较低与完全缓解相关。
  • PET 或增强 T1 加权 MRI 上肿瘤体积较大是较差总生存的显著预测因素。
  • 诊断时 MILAS 评分高与早期死亡(<1 年)相关。

核心结论

  • 基线小脑代谢和 sumMTV 可能预测 PCNSL 化疗结束时的缓解。
  • 基线肿瘤体积和 MILAS 是强预后因素。

研究设计与样本

  • 前瞻性多中心研究,纳入 2016 年 1 月至 2021 年 4 月间 60 岁以上免疫功能正常的初诊 PCNSL 患者。
  • 患者在大剂量甲氨蝶呤为基础化疗前行脑 [18F]FDG PET-MRI。

主要发现

  • 54 例新诊断弥漫大 B 细胞 PCNSL 患者中,52 例 PET 和 MRI 阳性,呈高 [18F]FDG 摄取和对比增强病变(SUVmax:27.7 [22.8-36])。
  • 高 [18F]FDG 摄取和代谢体积与基线低 ADCmean 值和高 CBF 显著相关。
  • 69% 的患者在诱导治疗结束时达到客观缓解,17 例为进展。
  • 诊断时较高的小脑 SUVmean 和较低的 sumMTV 是完全缓解的显著预测因素:分别为 6.4 [5.7-7.7] vs 5.4 [4.5-6.6](p = 0.04)和 5.5 [2.1-13.3] vs 15.9 [4.2-19.5](p = 0.01)。
  • 2 年总生存率为 71%,中位无进展生存期为 29.6 个月,中位随访 37 个月。

关键数值与推荐

  • 完全缓解预测因素:小脑 SUVmean 6.4 [5.7-7.7] vs 5.4 [4.5-6.6](p = 0.04);sumMTV 5.5 [2.1-13.3] vs 15.9 [4.2-19.5](p = 0.01)。
  • 2 年总生存率 71%,中位无进展生存期 29.6 个月,中位随访 37 个月。
  • 基线 SUVmax:27.7 [22.8-36]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Primary central nervous system lymphoma (PCNSL) incidence is rising among elderly patients, presenting challenges due to poor prognosis and treatment-related toxicity risks. This study explores the potential of combining [18F]fluorodeoxyglucose ([18F]FDG) PET scans and multimodal MRI for improving management in elderly patients with de novo PCNSL. METHODS: Immunocompetent patients over 60 years with de novo PCNSL were prospectively enrolled in a multicentric study between January 2016 and April 2021. Patients underwent brain [18F]FDG PET-MRI before receiving high-dose methotrexate-based chemotherapy. Relationships between extracted PET (metabolic tumor volume (MTV), sum of MTV for up to five lesions (sumMTV), metabolic imaging lymphoma aggressiveness score (MILAS)) and MRI parameters (tumor contrast-enhancement size, cerebral blood volume (CBV), cerebral blood flow (CBF), apparent diffusion coefficient (ADC)) and treatment response and outcomes were analyzed. RESULTS: Of 54 newly diagnosed diffuse large B-cell PCNSL patients, 52 had positive PET and MRI with highly [18F]FDG-avid and contrast-enhanced disease (SUVmax: 27.7 [22.8-36]). High [18F]FDG uptake and metabolic volume were significantly associated with low ADCmean values and high CBF at baseline. Among patients, 69% achieved an objective response at the end of induction therapy, while 17 were progressive. Higher cerebellar SUVmean and lower sumMTV at diagnosis were significant predictors of complete response: 6.4 [5.7-7.7] vs 5.4 [4.5-6.6] (p = 0.04) and 5.5 [2.1-13.3] vs 15.9 [4.2-19.5] (p = 0.01), respectively. Two-year overall survival (OS) was 71%, with a median progression-free survival (PFS) of 29.6 months and a median follow-up of 37 months. Larger tumor volumes on PET or enhanced T1-weighted MRI were significant predictors of poorer OS, while a high MILAS score at diagnosis was associated with early death (< 1 year). CONCLUSION: Baseline cerebellar metabolism and sumMTV may predict response to end of chemotherapy in PCNSL. Tumor volume and MILAS at baseline are strong prognostic factors.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rozenblum L, Galanaud D, Houillier C, et al. [18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network. Eur J Nucl Med Mol Imaging. 2023. PMID: 37462774. doi:10.1007/s00259-023-06334-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。